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Abstract: Hyperleukocytosis is commonly defined as a white blood cell (WBC) count exceeding 50-100 x 10
9
 L
-1
 in 
peripheral blood and can be seen in newly diagnosed leukemias. Increased WBC count can lead to increased blood 
viscosity, leukocyte aggregation, and consequently stasis in blood vessels. Hyperleukocytic leukemia is associated with 
a risk of organ failure and early death secondary to leukostasis. The main sites that tend to be injured are the central 
nervous system (CNS) and lungs. The goal of the treatment of hyperleukocytosis and/or leukostasis is to remove 
leukocytes or blasts from the peripheral circulation as soon as possible and to prevent or reduce acute symptoms of 
leukostasis. The cytoreduction can generally be achieved by leukapheresis and/or some chemotherapeutic agents 
before starting induction chemotherapy. Leukapheresis is an effective and safe procedure which can be used for 
symptomatic relief, some special and rare conditions (serious respiratory failure, CNS involvement, priapism), or 
prophylactically. The supportive care has to be a part of the treatment in order to prevent tumor lysis syndrome or 
coagulopathy. The difference of hyperleukocytosis and leukostasis, pathophysiology and clinical presentation of 
leukostasis, and treatment options of hyperleukocytosis and/or leukostasis in the light of the current literature will be 
discussed in this review.  
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1. INTRODUCTION 
Hyperleukocytosis can be seen in newly diagnosed 
acute leukemias, especially acute myeloid leukemia 
(AML) [1]. Some authors have demonstrated that 
hyperleukocytosis in AML patients is associated with 
higher early mortality rates [2, 3] as well as lower 
complete remission and long-term survival rates [2]. 
The presence of hyperleukocytosis is associated with 
severe morbidity and mortality, as a result of 
associated leukostasis, tumor lysis syndrome, or 
coagulopathy [1].  
Leukostasis, a medical emergency situation, refers 
to hyperleukocytosis combined with organ failure. 
Because of its poor prognosis and the high incidence of 
early mortality of patients with leukostasis [4, 5], prompt 
and efficient therapy is needed. For this purpose either 
medical (hydroxyurea/low-dose chemotherapy), 
invasive (leukapheresis) or combined procedures 
should be preferred by physicians. Leukapheresis is a 
safe procedure [6-9] and provides a rapid and effective 
cytoreduction in hyperleukocytic patients with or 
without leukostasis [5, 7, 10-12].  
The clinical sign and symptoms, pathophysiology, 
and finally basic treatment strategies of leukostasis will 
be reviewed. Evidence-based data about the 
experience of leukapheresis in symptomatic patients 
with hyperleukocytosis or its prophylactic use are also 
discussed extensively in the current review.  
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2. HYPERLEUKOCYTOSIS 
Hyperleukocytosis has been variably defined as a 
white blood cell (WBC) count exceeding 50 x 10
9
 L
-1
 [2, 
11] or 100 x 10
9
 L
-1
 [12, 13]. The incidence of 
hyperleukocytosis is 5-13% for adult AML, while is 10-
30% in acute lymphoblastic leukemia (ALL) [14]. 
Although hyperleukocytosis is more commonly 
occurred in patients with ALL than those with AML, the 
frequency of leukostasis is higher in AML patients 
compared to ALL patients. Monocytic subtypes of AML 
(FAB M4Eo, M5a) [15], the microgranular variant acute 
promyelocytic leukemia (APL-M3v) [16], t(4;11) (q21; 
q23) associated ALL and t(9;22) positive ALL [17, 18] 
has been linked with hyperleukocytosis. In contrast, 
some genetic abnormalities such as t(8;21), 
chromosome 5 and/or 7 abnormalities are associted 
with low WBC counts [11].  
The critical threshold of WBC count for symptomatic 
hyperleukocytosis or leukostasis is variable in different 
leukemia types (Table 1). Leukostasis is seen most 
frequently in chronic myeloid leukemia (CML) and AML 
patients. With respect to the “rheological theory”, 
myeloblasts are bigger than lymphoblasts and 
lymphocytes, and therefore leukostasis is more 
common in myeloid malignancies than in lymphocytic 
ones. On the other hand, not only the quantitave or 
rheologic properties of circulating cells, but also the 
qualitative properties of these cells may be related to 
leukostasis development. Soares et al. [19] have 
reported 16 leukemic patients with pulmonary 
leukostasis and with less than 50 x 10
9
 L
-1
 circulating 
leukocytes. The authors have suggested that 
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pulmonary leukostasis in the absence of 
hyperleukocytosis may be triggered by the presence of 
circulating blasts or the affinity of neoplastic cells for 
the pulmonary endothelium. More recently, a significant 
association between AML cell expression of the CD11c 
membrane molecule and a high risk of early death in 
leukocytosis have been shown [12]. Furthermore, an 
experimental diabetic retinopathy model performed by 
Serra et al. showed that CD11b (+) bone marrow-
derived monocytes expressing high levels of CCR5 
were the major subset of leukocytes responsible for the 
pathogenesis of retinal capillary leukocytosis [20]. Both 
these observations [12, 19] indicate that the biological 
characteristics of AML cells are also seem to influence 
the development of leukostasis.  
3. LEUKOSTASIS 
“Leukostasis” is defined as hyperleukocytosis 
concurrent with organ dysfunction due to tissue 
hypoxia, tissue infiltration or coagulopathy [12]. 
Pathologically, the definition is as follows: “the 
morphological evidence of intravascular accumulation 
of leukemic blasts occupying most or all of the vascular 
lumen, with or without the presence of fibrin” [21]. With 
respect to this definition, the activation of the 
coagulation cascade is not necessarily in the 
pathogenesis of leukostasis.  
Vascular obstruction due to sludging of high WBC 
count or blastic cells can lead to tissue hypoxia and 
eventually organ failure. The main sites tend to be 
affected from the leukostasis are the lungs and central 
nerve system (CNS) including retina [1]. Rarely, acute 
leg ischemia [22], renal vein thrombosis [23], priapizm 
[24], or splenic rupture [25] can occur.  
3.1. Clinical Presentation 
The clinical manifestations are reflective of the 
organ systems where affected by leukocyte/blast stasis 
and relevant tissue hypoxia. The most common 
symptoms/signs in a study conducted by Porcu et al. 
[13] revealed respiratory distress (39%), coagulopathy 
(31%), neurological symptoms (27%), and renal failure 
(14%). Pulmonary symptoms include tachypnea, 
dyspnea, and hypoxemia, with the presence of 
auscultatory rales and/or rhonci on physical 
examination. Chest imaging will reveal bilateral 
interstitial or alveolar infiltrates [1, 26]. The neurologic 
symptoms may highly range from less severe 
symptoms such as mild tinnitus, headache, and 
dizziness to severe threatening ones including delirium, 
intracranial hemorrhage, and coma. On physical 
examination, focal deficits and retinal hemorrhages 
may be present. The other target organs are the 
kidneys and heart presenting with azotemia and 
arrhythmia [26]. 
Leading symptoms of leukostasis are generally non-
spesific. Furthermore, it should be kept in mind that a 
combination of these sign/symptoms can be detected 
in the same patient at presentation. For example in a 
newly diagnosed acute myeloid leukemia patient with 
symptomatic hyperleukocytosis; thrombocytopenia, 
intracranial hemorrhage due to low platelet counts, 
renal insufficieny induced by secondary tumor lysis 
syndrome, an impaired coagulation test profile, and 
additionally some neurologic symptoms such as visual 
abnormalities may be occurred at the same time.  
3.2. Laboratory 
Laboratory tests are required to confirm a clinical 
suspician of leukostasis. Nevertheless, hyperelevated 
Table 1: Critical WBC Count for The Development of Hyperleukocytosis Symptoms or Leukostasis in Different Kind of 
Leukemias 
 Disease Subtype Threshold WBC Count  Reference 
CML  > 200 x 10
9
 L
-1
 Bruserud et al.
7
 
AML    
 M4Eo > 100 x 10
9
 L
-1
 Szczepiorkowski et al.
39
 
 M5a > 100 x 10
9
 L
-1
 Szczepiorkowski et al.
39
 
 APL > 10 x 10
9
 L
-1
 Ganzel et al.
1 
ALL  > 400 x 10
9
 L
-1
 Szczepiorkowski et al.
39 
CLL  > 1.000 x 10
9
 L
-1
 Ganzel et al.
1 
Abbreviations: WBC: White blood cell; CML: Chronic myeloid leukemia; AML: Acute myeloid leukemia; ALL: Acute lymphoblastic leukemia: CLL: Chronic 
lymphocytic leukemia. 
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WBC counts may give rise to some erroneus laboratory 
results such as pseudothrombocytosis, pseudo- 
hypoxemia due to leukocyte larcency, pseudo- 
hyperkalemia, pseudohypoglycemia, and prolonged 
coagulation tests [26]. 
3.3. Diagnosis and Prognosis 
Firstly, the clinicians must be aware of this 
syndrome. Despite its characteristic clinical 
presentation, the diagnosis of leukostasis is rarely 
made accurately [1]. A high clinical suspicion may lead 
and guide the physician to take the proper steps for 
making a quick and correct diagnosis. At this point, a 
more objective approach recommended by Novotny et 
al. [27] should be prefered. The authors developed a 
symptom-based grading score in order to predict the 
probability of leukostasis in leukemic patients with 
hyperleukocytosis (Table 2). Piccirillo et al. [28] 
retrospectively showed that “very high probability” 
group had a significant higher risk of early mortality. 
Adverse prognosis was associated with age, 
respiratory stress, presence of coagulopathy, 
neurological symptoms and renal failure [13].  
3.4. Pathophysiology 
Despite the exact mechanism of leukostasis is not 
clear, there are two main hypotheses. According to the 
“rheological theory” [29] blood viscosity was 
determined by the deformability of individual cells and 
the volume of the cell fraction in the blood. This means 
that the larger (myeloblasts vs lymphoblasts/ 
lymphocytes) and less deformable cells (blasts vs 
mature WBCs) as well as higher cell counts will result 
in increased blood viscosity and leukostasis risk. The 
other leading theory, “blast-endothelial cell interaction” 
[30], is based on the activation of endothelial cells by 
the high concentration of blasts. With respect to the 
proposed mechanism, increased cytokine release 
(especially tumor necrosis factor , interleukin 1) [31], 
adhesion molecules (selectins, vascular cell adhesion 
molecule-1) [31], and proteolytic enzymes (matrix 
metalloproteases-9= MMP-9) [32], endothelial cell 
damage and extravasation of AML cells may contribute 
to blast cell recruitment. Alterations of adhesion 
molecule pattern in peripheral blood blasts compared 
with bone marrow blasts may be related with the ability 
of blast to circulate or leukaemisation [33]. Both 
mechanisms seem to play important roles in the 
pathophysiology of leukostasis syndrome.  
As mentioned before, monocytic differentiation of 
AML cells has an important role in promoting 
hyperleukocytosis and subsequently, leukostasis. 
Interestingly, the nucleophosmin-1 mutation is highly 
associated with monocytic morphology and low 
expresion of the CD34 stem cell marker [34]. Similarly, 
MMP-9 may give rise to the tissue damage especially 
for AML cells with monocytic features [32, 35, 36].  
3.5. Treatment Strategies  
The principles of managing patients with 
hyperleukocytosis or leukostasis is quite similar. 
However, the clinican must keep in mind that 
leukostasis syndrome is a medical emergeny. 
Interventions should be started immediately. The main 
 Table 2: A Symptom-Based Grading Score to Predict the Probability of Leukostasis (no Obvious other Cause)
*
 
Group Probability Severity of symptoms Pulmonary symptoms Neurologic symptoms Other organ systems 
0 Not present No limitations No symptoms and no 
limitations in ordinary 
activities 
No symptoms  No symptoms 
1 Possible Slight limitations Mild symptoms and slight 
limitation during ordinary 
activity, comfortable at rest 
Mild tinnitus, headache, 
dizziness 
Moderate fatigue 
2 Probable Marked limitations Marked limitation in activity 
because of symptoms, 
even during less than 
ordinary activity, 
comfortable only at rest 
Slight visual disturbances
**
, 
severe tinnitus, headache, 
dizziness 
Severe fatigue 
3 Highly probable Severe limitations Dyspnea at rest, oxygen or 
respirator required 
Severe visual disturbances
**
 
(acute inability to read), 
confusion, delirium, 
somnolance, intracranial 
haemorrhage 
Myocardial infarction, 
priapism, ischemic 
necrosis 
*
Taken from the reference 27; 
**
Blurred vision, diplopia, hemianopia 
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goals of the treatment is to reduce the leukemic burden 
and to support the patient. The cytoreduction can be 
achieved by either medical (low-dose chemotherapy/ 
hydroxyurea) or mechanical (leukapheresis) ways. At 
this point, no generally accepted guidelines exist. All 
acute leukemia patients have to receive an induction 
chemotherapy, and both these efforts can be termed as 
a “pre-therapy” which help the patient to undergo an 
induction chemotherapy without complication. There 
are also some anectodal reports of successful 
pulmonary irradiation [37].  
With regard to its poor prognosis, some clinicians 
also tend to treat asymptomatic hyperleukocytosis in 
order to prevent the imminent symptoms of leukostasis 
[2].  
3.6. Supportive Care 
Supportive management basicly include close 
monitorisation of the patient, and efforts to prevent or 
minimize the catastrophic consequences of 
hyperleukostasis including tumor lysis syndrome and/or 
disseminated intravascular coagulation. For this 
purpose aggressive intravenous fluid support, 
allopurinol or rasburicase, and transfusion of blood 
components should be administered in selected cases. 
Redundant packed red cell transfusions should be 
avoided due to risk of increasing blood viscosity [26].  
4. LEUKAPHERESIS 
Leukapheresis refers to the withdrawal of whole 
blood, seperation and retention of WBCs, with the 
return of remaining constituents to the patient. During 
the procedure, the WBCs are concentrated and 
efficiently removed from the circulation [1]. In addition, 
leukapheresis increases the fraction of bone marrow 
leukemic cells that are in the S-phase of cell cycle [38].  
A continuous flow device is commonly preferred to 
process a 2 volume exchange or 10 L of whole blood. 
A 2 volume exchange can remove 87% of the 
component. The average volume of the WBC product 
collected is 600 mL. Patient’s size, the WBC count, and 
the volume of whole blood processed can also alter the 
product volume [1].  
4.1. Indications 
The American Society for Apheresis (ASFA) 
recommendations [39] for performing leukapheresis in 
acute leukemia patients are as follows: 
1. Hyperleukocytosis with symptoms of leukostasis 
(grade 1B recommendation), 
2. Sufficiently high WBC counts (see Table 1) to 
consider prophylactic apheresis (grade 2C 
recommendation).  
Serious respiratory failure or CNS involvement are 
currently regarded as indications for leukapheresis [39]. 
In certain rare medical emergencies, such as priapism 
[24, 40], leukapheresis will be an imperative treatment 
modality. For patients presenting with priapism, a 
combined modality approach including cytoreduction 
and local intracavernous therapy should always be 
considered [7, 40]. The use of leukapheresis in the 
setting of newly diagnosed CML during pregnancy 
have been reported [41-43]. Corrobation of respiratory 
symptom relief by therapeutic leukapheresis with 
physiological measurements may justify it in pregnant 
women with CML [44]. 
Nonetheless, implementation of leukapheresis in 
patients with APL is controversial, even some groups 
cautioned against using apheresis in this setting [45].  
4.2. Monitoring of the Patient 
As mentioned before, hyperleukocytosis is 
associated with an increased risk of tumor lysis 
syndrome and/or coagulopathy. Due to these 
catastrophic complications serum urea, creatinine, uric 
acid, potassium, calcium, phosphorus, lactate 
dehydrogenase levels, and at least a basal coagulation 
profile (prothrombin time, activated partial 
thromboplastin time) has to be studied by the attending 
physician.  
The symptomatic improvement is the best way to 
decide the efficacy of leukapheresis. Additionally, pre- 
and post-apheresis WBC counts and leutokrit values, 
or the percent reduction in the circulating WBC mass 
can be beneficial for monitoring [1]. 
% Reduction in the Circulating WBC Mass= 
[WBC count in the collection / The patient’s circulating 
WBC count before the procedure] x 100  
4.3. Number of the Procedures  
Daily leukapheresis should be continued until 
clinical improvement or reaching a WBC count of less 
than 100 x 10
9
 L
-1 
[1, 5]. A single procedure can reduce 
the circulating WBC count by 20-50%. To decrease 
50% of peripheral WBC count corresponds to removing 
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85% of the circulating WBC mass [1]. In Bruserud’s 
series, the average number of leukapheresis for each 
AML patient was 2.2, and the mean WBC count 
reduction was 71% corresponding to a mean absolute 
WBC reduction of 219 x 10
9
 L
-1
 [7]. Similarly in a more 
recent study by Berber and his colleques, the median 
number of procedures for hyperleukocytic AML patients 
was reported to be 2 per patient [1]. When there is 
recruitment to the circulation from the bone marrow 
during the procedure or when the symptoms dictate, 
the additional procedures may be required [1].  
4.4. Complications 
Leukapheresis seems to be a safe procedure both 
with regard to immediate complications [5-9] and 
effects on long-term prognosis [7]. Short-term 
complications include hypocalcemia associated with 
citrate toxicity, anemia and thrombocytopenia due to 
multiple procedures, and cathater-related compli- 
cations. Bruserud et al. [7] did not observe any serious 
side effects during or immediately after 35 apheresis 
procedures performed for 16 hyperleukocytic leukemia 
patients. De Santis et al. [5] performed 21 
leukapheresis procedures that begun within 12 hour 
after admission for 15 consecutive AML patients with 
the symptoms of leukostasis. Similarly, they did not 
report any severe side effects.  
4.5. Efficacy 
Although several analyses in retrospective fashion 
[5, 10, 11] have been published addressing the use of 
leukapheresis in hyperleukocytosis, no randomised, 
prospective studies of the efficacy of leukapheresis on 
early mortality or long-term prognosis are available. 
The time interval for defining early deaths varied 
from 7 to 42 days of diagnosis or presentation [46]. 
Porcu et al. [13] reported a first-week mortality rate of 
27.1% and did not find any correlation between early 
mortality rate and the degree of cytoreduction in 48 
patients who underwent daily leukapheresis until WBC 
count < 100 x 10
9
 L
-1
. In a retrospective experience 
[10], early deaths occurred in only 3.8% of the 53 AML 
patients who were treated with leukapheresis, while 
leukapheresis was found to be ineffective in 21 patients 
(~40%). The early mortality rates were reported to be 
57% and 47%, respectively in two smaller patient 
groups [4, 5] with hyperleukocytic leukemia. But it 
should be noted that both these studies constituted of 
patients with symptomatic hyperleukocytosis.  
Giles et al. [11] compared two AML patient groups 
who did and did not undergo leukapheresis. Two-
weeks early mortality rates, as well as long-term 
survival results did not differ for patients receiving 
apheresis or not. However, the independent predictors 
of survival at 2 weeks were found to be apheresis, 
younger age, lower WBC count and low performance 
status. Chang et al. [6] showed that leukapheresis had 
no significant influence on early mortality or the 
incidence of intracranial hemorrhage. The most 
significant risk factors for early death were age  65, 
respiratory failure, and having two or more symptoms 
of leukostasis. Finally Bug et al. [12] reviewed their 
findings and they emphasized that leukapheresis 
significantly lowers the risk of early mortality by day 21 
(16% vs 32%, respectively; p= .015), while no 
significant difference was noted in terms of complete 
remission or overall survival rates. Dyspnea, elevated 
creatinine, higher lactate dehydrogenase serum levels 
were independent risk factors for early death. With 
respect to this benefit, the authors also remarked that 
leukapheresis was accepted as a standard procedure 
for hyperleukocytic AML patients whom admitted to 
their institution.  
Most recently, Berber et al. [8] reported their results 
generated from 31 AML patients with 
hyperleukocytosis. The most common AML subtype 
was AML-M2. Early and total mortality rates were 
16.1% and 58.1%, respectively. 14 patients 
experienced leukapheresis for symptomatic relief, while 
17 received it prophylactically. No significant 
differences were noted between two groups in terms of 
leukapheresis effectiveness, mean survival time, early 
and total mortality rates. To the best of our knowledge, 
this is the first study, which compared leukapheresis in 
terms of leukapheresis indications. The same group 
has also compared the efficacy of leukapheresis 
between elderly ( 65 years-old; n= 18) and younger (< 
65 years-old; n= 21) acute leukemia patients [9]. There 
were no statistically significant differences between the 
two groups with respect to sex, diagnosis, initial 
leukocyte count, lactate dehydrogenase level, number 
of leukapheresis procedures, rates of side effects, or 
early and total mortality. In addition, their cut-off WBC 
counts for prophylactic leukapheresis was different 
from ASFA’s recommendations. The leukocyte counts 
exceeding 50 x 10
9
 L
-1
 for AML M4-M5, > 100 x 10
9
 L
-1
 
for AML subtypes other than M3, M4, and M5, and > 
200 x 10
9
 L
-1
 for ALL patients were defined as 
thresholds for the prophylactic apheresis procedure. 
The latter study of the Turkish group seems to be the 
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first study about the effectiveness of leukapheresis in a 
geriatric population.  
4.6. Leukapheresis or Medical Treatment for Pre-
Therapy? 
To decide the initial therapeutic option in a patient 
with symptomatic hyperleukocytosis is still contro- 
versial. A systematic review and meta-analysis [46] 
including 21 studies and in 1500 AML patients with 
hyperleukocytosis (WBC > 100 x 10
9
 L
-1
) showed that 
neither leukapheresis strategy (universal or selected 
use) nor hydroxyurea/low-dose chemotherapy 
influenced early deaths during first induction.  
The timing of chemotherapy also varies between 
the studies. Concomitant therapy with a possible 
combined effect of leukapheresis and chemotherapy 
was suggested by De Santis et al. [5]. Some authors 
emphasized the importance of early, the same day as 
the first apheresis [11] or within 24 hours [5], 
cytoreductive chemotherapy. Thiebaut et al. [10] 
observed a recruitment of bone marrow cells into the S 
phase after the apheresis procedure. In this setting, 
early initiation of cell-cycle specific chemotherapeutic 
agents may provide additional benefits. However, a 
delayed chemotherapy intervention later than 48 hours 
after admission was significantly (p= .001) associated 
with increased early mortality [6].  
It must be noted that the final decision about this 
matter of debate depends on some factors; patient 
characteristics, physician preferences, and the policy of 
the institution.  
5. CONCLUSIONS 
Leukapheresis offers a safe and effective treatment 
modality for cytoreduction in selected indications. 
Owing to its dismal prognosis, leukapheresis is 
commonly preferred in hyperleukocytic patients with a 
high risk of leukostasis, or some rare emergent 
conditions including respiratory failure, CNS 
involvement or priapism. In asymptomatic patients with 
hyperleukocytosis, pre-therapy with hydoxyurea/low-
dose chemotherapy and supportive care should be 
prioritized rather than leukapheresis.  
While some retrospective analyses demonstrated 
that leukapheresis reduces early mortality in 
hyperleukocytic leukemia patients, the effect of 
leukapheresis on long-term prognosis of leukemia 
patients is not well documented. Further randomised, 
prospective clinical studies on leukapheresis in the 
treatment of hyperleukocytosis are needed. 
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